Meridian develops Po-210 radiopharmaceuticals for targeted cancer treatments, managing the entire supply chain from isotope production to therapeutic development. Their platform provides biotech and pharmaceutical partners with a scalable, high-purity Po-210 supply to advance next-generation cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Metastatic cancers in the bone are often painful and underserved by existing treatments, leading to a poor prognosis for patients. Current therapies may not effectively target cancer cells within the bone microenvironment, resulting in limited efficacy and significant side effects. The need for more precise and effective treatments for bone metastases, particularly in breast, prostate, and lung cancers, remains a critical unmet need.
Solution
Meridian Radiopharmaceuticals is developing targeted radiotherapies to treat cancer that has metastasized to the bone. Their approach involves linking Zoledronic Acid with phosphorous-33, a beta-emitting isotope, to deliver targeted beta radiation directly to the sites of metastases. This method aims to relieve symptoms and attack cancer cells in the bone while minimizing harm to healthy tissue. By focusing on precision radiotherapy, Meridian seeks to transform bone metastases from a terminal diagnosis into a treatable condition, offering renewed hope for patients with advanced cancer.
Target Audience
The primary target audience includes patients with breast, prostate, and lung cancers that have metastasized to the bone, as well as oncologists and healthcare providers specializing in cancer treatment.
Features
- Targeted radiotherapy using Zoledronic Acid linked with phosphorous-33 (P-33)
- Delivers beta radiation directly to bone metastases
- Development pipeline includes drug candidates for breast, prostate, and lung cancers
- Aims to minimize harm to healthy tissue